Ledipasvir (Harvoni): A Case Study

used as a first line treatment for the HSV. The regression data denote that the

Ans) – It is used for ETOH withdrawal drip like other hospitals use Ativan for it.

Treatment is varied. There are several drugs used to treat hepatitis in the United States. Intron A, Epivir-HBV, Pegasys, Baraclude, Hepsera, Viread, and Tyzeka are the only FDA approved drugs that have been shown to slow the virus and decrease liver damage and in some cases the virus is killed completely ("Hepatitis Treatments," n.d.). Ultimately vaccination is the best way to prevent HBV. The vaccine has been found to be effective and safe. Administration is given over a 6 month time and consists of 3-4 shots ("Hepatitis B," n.d.) and is estimated to be 95% effective. Everyone should be vaccinated but the

A review of the records reveals the member to be an adult male with a birth date of 11/30/1964. The member has a diagnosis of chronic hepatitis C virus, genotype 1a. The member’s treating provider, Steven Zierer, MD has recommended treatment with the prescription medication, Harvoni 90mg – 400mg 1 tab daily for 12 weeks for this member.

The approved medicine is a combination of two medicines called Harvoni. The combination holds antiviral medicines Sofosbuvir and Ledipasvir. The effective combination takes around 8-24 weeks to heal the pain of HCV. Patients taking this new combination work as much as lower risk of dangerous side effects related to the typical treatment for hepatitis C virus. HCV medication online is available with this useful combination. Regrettably, the cost of these medicines is higher than normal medications. The higher cost of the medication simply means that some patients who require it might not be appropriate for it, but it has been called as a most important breakthrough in the treatment of hepatitis C.

About 4.1 million people in Americans have the positive antibody to hepatitis C virus (HCV), and about 75 percent have permeant infection. Additionally, most of the infections happened 20 to 40 years ago, before the finding of HCV. Hepatitis C increased from 7,000 to 13,000 deaths in 2005. Furthermore, HCV develops slowly which increases the risk of severe complications in the infected people. Identification, death, and treatment are predicted to affect 35,000 by 2030. The Center for Disease Control (CDC) used antiviral therapy with PEGylated in clinical trials (Kalichman, Washington, Kegler, Grebler, Kalichman, Cherry, & Eaton, 2015). The CDC recommends a HCV one time test for people born between 1945 and 1965. The objective of this study was to thoroughly evaluate the amount of substance abusers infected with hepatitis C in the United States. Additionally, to observe the treatment of HCV. Currently Medicaid and Medicare repayment standards for sofosbuvir were calculated in all states, including the District of Columbia. Medicaid and Medicare covered the drug based on the following conditions; liver disease stage, HIV, and drug use. Approximately 42 states reimbursed the following criteria up to 74 percent for the drug sofobuvir. About two-thirds of the United States restricted the treatment centered on prescriber type. About 88 percent included drug abuse in their sofosbuvir admissibility measures. Finally, 50 percent required a date of abstinence and 64 percent required

Many people don’t understand how dangerous Hepatitis C is because it is not commonly known about as much as Hepatitis A or B. This disease is however very serious. Although frequently asymptomatic in time the virus can lead to cirrhosis, liver cancer and liver failure. Symptoms of HCV are jaundice (yellowing of the eyes), stomach pain, nausea and fatigue. Treatment options for the disease, if caught early enough is a combination of medications or depending on the degree of damage, a liver transplant. ”For some people, hepatitis C is a short-term illness but for 70%-85% of people who become infected with

This formula can be used to weaken the liver, it is also very beneficial for this disease.

Until 2011, the main therapy against the infection was Pegylated-interferon (Peg-IFN) and the ribavirin (RBV) treatment (11). Interferon is a type of protein that stimulates the immune system and helps halt the virus from spreading throughout the body. Pegylated-interferon is a combination of three types of interferon, including polyethylene (PEG), which helps the treatment remain in the body for a longer time period. Ribavirin is a medication that helps stop the HCV virus from replicating. It is commonly used in combination with interferon, which is referred to as the “Peg/riba therapy.” This combination therapy is more effective than the interferon itself. However, these medications do not have a one hundred percent cure rate and it was reported

It is commonly used as an antimicrobial. Currently, research is being done to determine the viability of using the molecule to prevent the spread of HIV and to destroy cancer cells.

If someone is getting tested for Hepatitis C, they will first take an antibody test. This test will detect if antibodies are present in the blood, which will tell if the person has ever had Hepatitis C, not if they currently possess it (“Who Should”). If the antibody test comes back positive, a qualitative test will then be run. This test declares tells if someone is currently infected with Hepatitis C. A quantitative test can also be run, which shows the amount of Hepatitis C that is in the blood (“Who Should”). There are two main medications that are used to treat Hepatitis C. The first being Pegylated Interferon and another being Ribavirin. Both medications are used for the treatment of adult patients with chronic liver disease (FDA). These medications are used in place of the vaccine that has not been created for Hepatitis C. Therefore, Hepatitis C can be detected easily and is treatable.

Sovaldi also known as Sofosbuvir is one of the latest anti- HCV drug in the market (Ollove, 2014). The drug has already been approved by the United States Food and Drug Administration (FDA) having gone through years of clinical trials. The drug’s claim to fame other than its high cost ($84,000 for 12 weeks of treatment or $1000 for one pill) is that it boasts of shorter treatment duration of about 3 months

2. Individuals known to have chronic hepatitis C tested positive with the C 100-3 assay.

In general, a patient is infected with only one hepatitis C virus genotype. The strain of genotypes is not differentiated by the severity of the disease. However, there will make a distinction in the regimen and the duration of the treatment (CDC, 2016). Treatment for chronic HCV is based on guidelines from the Infectious Diseases Society of America (IDSA) and the American Associations for the Study of Liver Diseases (AASLD). The criteria of who should receive the treatment include how much the virus in the body, the strain of hepatitis C, the degree of liver inflammation or damage, comorbidity, and response to previous treatment (Infectious Diseases Society of America [IDSA], 2016). The highest priority for treatment should give to a patient with advanced fibrosis and compensated cirrhosis (IDSA, 2016). Moreover, treatment priority should provide to the patient who has a high risk of transmitting the disease from and to others, such as individuals who are active injection drug users and hemodialysis patients (IDSA, 2016).

Genotype 1 is the most common form of HCV. Even within a single genotype there may be some slight variations. “Genotyping is important to guide treatment because some viral genotypes respond better to therapy than others. The genetic diversity of HCV is one reason that it has been difficult to develop an effective vaccine since the vaccine must protect against all genotypes.” (WHO, 2011)